Health
US Tariffs on Pharmaceuticals Could Spark Global Trade Disruptions
The pharmaceutical industry is bracing for potential upheaval as the United States considers imposing tariffs on drug imports, a move that could send shockwaves across global markets. President Donald Trump has signaled his intent to impose a 25% tariff on pharmaceuticals as part of a broader strategy to bring drug manufacturing back to the US.
Speaking from the Oval Office on Wednesday night, Trump confirmed his administration’s plans to target the pharmaceutical sector.
“We’re going to be doing tariffs on pharmaceuticals to bring our pharmaceuticals back,” he stated.
While the move aims to bolster domestic production, experts warn that the tariffs could lead to unintended consequences, including higher drug prices and supply chain disruptions that would impact both American and European companies. The US, a major importer of pharmaceuticals, heavily depends on European manufacturers for specialized medications. In 2023 alone, the US imported $170 billion (€157 billion) worth of pharmaceutical products, with $127 billion (€117 billion) coming from the EU.
European Markets at Risk
European pharmaceutical firms are particularly vulnerable to the proposed tariffs. Ireland, a key hub for American pharmaceutical companies, could face severe economic repercussions. In 2023, Ireland exported over €80 billion worth of pharmaceuticals to the US, accounting for more than half of its total exports. Major US firms like Pfizer, Johnson & Johnson, and Eli Lilly have significant operations in Ireland, and potential tariffs could lead to job losses and reduced investment.
Denmark’s pharmaceutical sector, especially Novo Nordisk, is also at risk. The company, a leader in diabetes and obesity treatments, generates over 50% of its revenue from the US market. Increased costs due to tariffs could impact American patients while also denting Denmark’s economic growth. The success of Novo Nordisk’s weight-loss drugs like Ozempic and Wegovy has been a major driver of Denmark’s GDP, contributing nearly half of its economic growth in 2023.
Impact on Other European Nations
Beyond Ireland and Denmark, other European pharmaceutical hubs would also feel the strain. Belgium, home to Pfizer’s major European production facilities, exported over $73 billion in pharmaceuticals in 2024, with a quarter of those exports going to the US. Germany’s pharmaceutical and biotech industries, including major players like Bayer and BioNTech, could also face setbacks. France, Italy, and Switzerland—key exporters of vaccines, generics, and high-value specialty drugs—would experience supply chain disruptions and financial strain.
EU Retaliation on the Horizon?
If the US proceeds with tariffs, the European Union may impose retaliatory measures targeting American pharmaceutical companies. The European Commission is reportedly exploring countermeasures, including higher export costs for US firms such as Pfizer, Merck, and Johnson & Johnson.
Additionally, the EU could prioritize domestic pharmaceutical companies in government contracts and revive stalled regulatory reforms, such as the General Pharmaceutical Legislation (GPL) reform, which aims to strengthen Europe’s pharmaceutical sovereignty. The recently proposed Critical Medicines Act could also serve as a framework to counterbalance US trade policies.
With negotiations ongoing, the global pharmaceutical industry is closely watching developments, as any trade war in this sector would have far-reaching consequences for businesses, patients, and healthcare systems on both sides of the Atlantic.
Health
Europe Faces Growing Challenges in Meeting Medical Care Needs, EU Report Shows

A new report has highlighted stark disparities in healthcare access across Europe, revealing that a growing number of citizens face unmet medical needs due to systemic issues such as high costs and long waiting times.
According to the latest data from Eurostat and the Health at a Glance: Europe 2024 report, 3.8 per cent of EU residents aged 16 and over reported unmet medical needs in the past year. However, the percentage climbs significantly when focusing solely on individuals who actively required healthcare services — with some countries reporting unmet needs among over 20 per cent of this group.
The causes are twofold: healthcare system barriers, including long waiting lists and treatment costs, account for 2.4 per cent of all cases, while 1.4 per cent stem from personal reasons such as fear of doctors, lack of time, or lack of knowledge about available care.
Unmet healthcare needs vary widely across the continent. Estonia tops the list within the EU, with 15.5 per cent of people reporting unmet needs, followed closely by Greece and Albania, each over 13 per cent. Even wealthier Nordic countries show surprising figures — Denmark (12.2 per cent), Finland, and Norway (over 7.5 per cent) — despite high healthcare spending. Conversely, countries such as Germany (0.5 per cent), Austria (1.3 per cent), and the Netherlands (1.4 per cent) report the lowest levels, pointing to more efficient and accessible healthcare systems.
Cost is a dominant barrier in nations like Greece and Albania, where over 9 per cent of citizens cited unaffordable care. In contrast, long waiting times are the primary issue in countries like Estonia (12 per cent) and Finland (7.5 per cent).
Income inequality also plays a major role. On average, 3.8 per cent of low-income individuals across the EU report unmet needs due to healthcare system issues — more than triple the 1.2 per cent reported by higher-income groups. In Greece, that gap is particularly wide, with 23 per cent of low-income respondents affected.
Healthcare experts say these disparities reflect more than just economic factors. Dr. Tit Albreht, President of the European Public Health Association (EUPHA), noted, “Unmet health needs arise from different reasons, including how well healthcare governance integrates services to meet population needs.”
Industry leaders, such as Tina Taube of the European Federation of Pharmaceutical Industries and Associations (EFPIA), stressed the importance of timely access to diagnosis and treatment. “Unmet needs are context-specific,” she said. “It’s not just about product availability, but also healthcare system readiness.”
Andy Powrie-Smith of EFPIA added that patients in some European countries wait up to seven times longer than others for the same treatments due to regulatory delays and varying national infrastructures.
The findings underscore the need for a more coordinated, equitable healthcare strategy across the continent, especially as Europe faces the challenges of an ageing population and increasingly complex medical technologies.
Health
Chinese Nationals Charged in U.S. with Smuggling Toxic Fungus Labeled a Potential Agroterrorism Threat

U.S. federal authorities have charged two Chinese nationals in connection with smuggling a dangerous agricultural fungus into the country, a move investigators describe as posing significant national security risks.
Yunqing Jian, 33, and Zunyong Liu, 34, are accused of conspiracy, smuggling, making false statements, and visa fraud after allegedly attempting to bring Fusarium graminearum — a toxic fungus capable of devastating crops and harming humans and livestock — into the United States. The case was detailed in a court filing by the Federal Bureau of Investigation (FBI) in Detroit.
The fungus, which targets essential food staples like wheat, maize, barley, and rice, is described in a scientific journal cited by the FBI as a “potential agroterrorism weapon.” Experts warn that its spread could inflict serious damage on global food security and agricultural economies.
U.S. Attorney Jerome Gorgon Jr. emphasized the seriousness of the case, stating: “The alleged actions of these Chinese nationals, including a loyal member of the Chinese Communist Party, are of the gravest national security concerns.”
Jian made her first appearance in a Detroit federal court on Tuesday and remains in custody awaiting a bond hearing scheduled for Thursday. A court-appointed attorney for her initial appearance declined to comment.
According to the FBI’s complaint, the investigation began in July 2024 when Liu was stopped at Detroit Metropolitan Airport. During a routine screening, customs officials discovered suspicious red plant material in his backpack. Liu initially claimed not to know what it was but later admitted he planned to use it for research purposes at the University of Michigan, where Jian is currently employed and where Liu previously worked.
Authorities say Liu’s mobile phone contained an article titled “Plant-Pathogen Warfare under Changing Climate Conditions,” raising further concerns about the intended use of the samples. The FBI believes the two individuals were coordinating to introduce the pathogen into a U.S. research setting without proper clearance or oversight.
Liu was denied entry to the U.S. and deported in July. Charges against both individuals were filed this week, as prosecutors continue to investigate the scope of the alleged conspiracy.
The case underscores growing concerns in the U.S. over biosecurity and potential misuse of scientific research amid rising geopolitical tensions.
Health
US Expands Measles Vaccination Guidance Amid Global Surge in Cases
-
Business1 year ago
Saudi Arabia’s Model for Sustainable Aviation Practices
-
Business1 year ago
Recent Developments in Small Business Taxes
-
Politics1 year ago
Who was Ebrahim Raisi and his status in Iranian Politics?
-
Business11 months ago
Carrectly: Revolutionizing Car Care in Chicago
-
Business11 months ago
Saudi Arabia: Foreign Direct Investment Rises by 5.6% in Q1
-
Technology1 year ago
Comparing Apple Vision Pro and Meta Quest 3
-
Politics1 year ago
Indonesia and Malaysia Call for Israel’s Compliance with ICJ Ruling on Gaza Offensive
-
Sports10 months ago
Keely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m